One-year safety and tolerability profile of pridopidine in patients with Huntington disease

Neurology

Volumn 80, Issue 12, 2013, Pages 1086-1094

  Squitieri, Ferdinando ^a   Landwehrmeyer, Bernhard ^b   Reilmann, Ralf ^c   Rosser, Anne ^d   De Yebenes, Justo Garcia ^e   Prang, Allan ^f   Ivkovic, Jelena ^f   Bright, Jeremy ^g   Rembratt, Åsa ^f  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f NEUROSEARCH A S   (Denmark)

^g Oxford Pharma Genesis Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; PLACEBO; PRIDOPIDINE;

ABNORMAL BEHAVIOR; ADULT; AGITATION; ANXIETY; ARTICLE; BALANCE DISORDER; BLURRED VISION; CHOLANGITIS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FALLING; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD INJURY; HEADACHE; HUMAN; HUNTINGTON CHOREA; INSOMNIA; INTOXICATION; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENORRHAGIA; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SOMNOLENCE; SUICIDE ATTEMPT; THORAX PAIN; UNIFIED HUNTINGTON DISEASE RATING SCALE; VITAL SIGN;

ADULT; DEPRESSION; DIZZINESS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PIPERIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876208391     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182886965     Document Type: Article

References (22)

1. Walker FO. Huntington's disease. Lancet 2007;369: 218-228.
2. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-1068.
3. Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 1999;97:613-622.
4. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007;130:2858-2867.
5. Oyanagi K, Takeda S, Takahashi H, Ohama E, Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 1989;26:13-19.
6. Spargo E, Everall IP, Lantos PL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993;56:487-491.
7. Ciarmiello A, Cannella M, Lastoria S, et al. Brain whitematter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006;47:215-222.
8. Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092.
9. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009; 3:CD006456.
10. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009;3: CD006455.
11. Burgunder J-M, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. Plos Curr Epub 2011;3:RRN1260.
12. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 2012;200:387-392.
13. Dyhring T, Nielsen EØ, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010;628:19-26.
14. Ponten H, Kullingsjö J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 2010;644:88-95.
15. Waters S, Klamer D, Tedroff J, et al. Pridopidine: effects on corticostriatal pathways controlling motor functions. Clin Genet 2011;80(suppl 1):33.
16. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996; 11:136-142.
17. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057.
18. ICH Expert Working Group. Clinical safety data management: definitions and standards for expedited reporting-E2a, ICH Harmonised Tripartite Guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E2A/Step4/E2A-Guideline.pdf. Accessed October 31, 2012.
19. Waters S, Tedroff J, Kieburtz K. Validation of the modified motor score (mMS): a subscale of the Unified Huntington's Disease Rating Scale (UHDRS) motor score. Neurotherapeutics 2010;7:144.
20. Kieburtz K, on behalf of the HSG HART study investigators. A randomized, double-blind placebo-controlled trial of ACR16 in Huntington's disease. Neurotherapeutics 2011;8:135.
21. Paulsen JS, Ferneyhough Hoth K, Nehl C, Stierman L, on behalf of The Huntington Study Group. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 2005;162:725-731.
22. World Health Organization. Mental health: country reports [online]. Available at: http://www.who.int/mental-health/prevention/suicide/country- reports/en/. Accessed October 31, 2012.